MEDICINES CO /DE filed this form 10-Q on 15 May 2002
<PAGE> 1 EXHIBIT 10.2 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. STUDY AND EXCLUSIVE OPTION AGREEMENT entered into on this 5th day of March 2002 (the "Effective Date") by and between ASTRAZENECA AB, a company incorporated under the laws of Sweden with its registered office at S-151 85 Sodertalje, Sweden ("ASTRAZENECA") and THE MEDICINES COMPANY, a company incorporated under the laws of Delaware with its registered office at One Cambridge Center, Cambridge, Massachusetts 02142, United States ("TMC"); WITNESSETH WHEREAS, ASTRAZENECA performs research, development and marketing of pharmaceutical compounds and products inter alia in the cardiovascular therapy area; and WHEREAS, ASTRAZENECA has developed the intravenous product Clevidipine for indications such as the control of blood pressure; and WHEREAS, TMC performs development of pharmaceutical compounds and marketing of pharmaceutical products particularly in the cardiovascular therapy area; and WHEREAS, TMC may be interested in acquiring a license to develop and commercialise Clevidipine provided that the product fulfils certain clinical criteria; and
WHEREAS, ASTRAZENECA has expressed its interest to license Clevidipine to TMC and finds it to be in the mutual interest of the Parties that TMC may perform a certain clinical study to evaluate whether Clevidipine fulfils the criteria desired.